WHO Grade 3 Glioma Recruiting Phase 2 Trials for Temozolomide (DB00853)

Also known as: WHO Grade III Gliomas / Grade III Glioma / WHO Grade III Glioma

IndicationStatusPhase
DBCOND0146359 (WHO Grade 3 Glioma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04623931Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) GlioblastomasTreatment